Insulet Corp is a healthcare company specializing in the development and manufacturing of innovative insulin delivery systems for individuals with diabetes. The company is best known for its Omnipod Insulin Management System, a tubeless, waterproof device that allows users to deliver insulin discreetly and conveniently without the need for traditional syringes or infusion sets. Insulet is committed to enhancing the quality of life for diabetes patients by providing advanced technology solutions that simplify insulin management, improve glycemic control, and promote independence in self-care. Through ongoing research and development, Insulet aims to lead the way in diabetes management innovation. Read More
Shares of insulin delivery company Insulet Corporation (NASDAQ:PODD) fell 4.3% in the morning session after the company announced a change in its chief financial officer, a move that appeared to overshadow an otherwise positive update to its sales forecast.
Small-cap and blue-chip stocks advanced in Wednesday morning trading on Wall Street, while technology names lagged and the S&P 500 hovered near record levels as investors braced for the Federal Reserve's interest rate decision.
Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Flavia Pease will succeed Ana Maria Chadwick as Executive Vice President, Chief Financial Officer, effective September 30, 2025. Ms. Chadwick will become a Senior Advisor to Insulet to ensure a smooth transition.
Insulet has had an impressive run over the past six months as its shares have beaten the S&P 500 by 18%. The stock now trades at $337, marking a 35.7% gain. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index.
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors.
A select few continue to innovate and expand, setting themselves up for long-term success.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Cash-generating companies often have the flexibility to invest, return capital to shareholders, or navigate downturns.
The best of these businesses not only accumulate cash but deploy it strategically for growth.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the patient monitoring industry, including Insulet (NASDAQ:PODD) and its peers.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Eric Benjamin to Chief Operating Officer effective immediately. The Company also announced the appointment of Manoj Raghunandanan as Chief Growth Officer.
Exciting developments are taking place for the stocks in this article.
They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Growth is oxygen.
But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Lending support to his choice, BTIG analyst initiated coverage on Rocket Companies with a Buy rating and $25 price target. Cisco and Insulet also discussed.
Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the upcoming investor conferences (all Eastern Time):
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
